CompanyT4
Candel Therapeutics
Clinical-stage biotech developing viral immunotherapy platforms for solid tumors. Phase 3 results in prostate cancer, active trials in lung and brain cancer.
last observed
Activity Score
0
confidence 80 % · metrics-v1
Hiring Momentum 30d
—
not enough monitored evidence
Product Velocity
—
not enough monitored evidence
AI Adoption
0
confidence 60 % · metrics-v1
Corporate Change Index
0
confidence 64 % · cci-v1
10 active sensors·5 observations·0 historical changes·0 structured events·historical coverage 99 %·observed since 2026-09-16
Compare Candel Therapeutics with peers on activity, hiring, product velocity, AI adoption, locations and events.
Compare companies